NASDAQ:TFFP

TFF Pharmaceuticals Stock Forecast, Price & News

$12.12
-1.09 (-8.25 %)
(As of 04/12/2021 03:59 PM ET)
Add
Compare
Today's Range
$11.99
Now: $12.12
$13.10
50-Day Range
$12.96
MA: $14.94
$17.95
52-Week Range
$4.20
Now: $12.12
$21.14
Volume6,425 shs
Average Volume384,748 shs
Market Capitalization$280.46 million
P/E RatioN/A
Dividend YieldN/A
Beta2.47
TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform in the United States and Australia. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which has completed Phase I clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in the Phase I clinical trials used for the prevention of lung transplant rejection. It is also developing other dry powder products, such as Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various types of pain; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.
TFF Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TFFP
CUSIPN/A
CIKN/A
Phone737-802-1973
Employees4
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.50 per share

Profitability

Net Income$-11,870,000.00

Miscellaneous

Market Cap$280.46 million
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable

Headlines

TFF Pharmaceuticals Prices Offering of Common Stock
March 26, 2021 |  finance.yahoo.com
TFFP Mar 2021 15.000 put
March 3, 2021 |  in.finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.39 out of 5 stars

Medical Sector

681st out of 2,011 stocks

Pharmaceutical Preparations Industry

329th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$12.12
-1.09 (-8.25 %)
(As of 04/12/2021 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TFFP News and Ratings via Email

Sign-up to receive the latest news and ratings for TFFP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











TFF Pharmaceuticals (NASDAQ:TFFP) Frequently Asked Questions

Is TFF Pharmaceuticals a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TFF Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TFF Pharmaceuticals stock.
View analyst ratings for TFF Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than TFF Pharmaceuticals?

Wall Street analysts have given TFF Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but TFF Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting TFF Pharmaceuticals?

TFF Pharmaceuticals saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 305,300 shares, an increase of 37.6% from the February 28th total of 221,800 shares. Based on an average daily volume of 362,700 shares, the days-to-cover ratio is currently 0.8 days. Currently, 1.7% of the company's stock are sold short.
View TFF Pharmaceuticals' Short Interest
.

When is TFF Pharmaceuticals' next earnings date?

TFF Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for TFF Pharmaceuticals
.

How were TFF Pharmaceuticals' earnings last quarter?

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) released its quarterly earnings results on Wednesday, March, 10th. The company reported ($0.26) EPS for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.03.
View TFF Pharmaceuticals' earnings history
.

How has TFF Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

TFF Pharmaceuticals' stock was trading at $4.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TFFP shares have increased by 203.0% and is now trading at $12.12.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for TFFP?

4 Wall Street analysts have issued twelve-month price targets for TFF Pharmaceuticals' stock. Their forecasts range from $18.00 to $37.00. On average, they anticipate TFF Pharmaceuticals' stock price to reach $29.50 in the next twelve months. This suggests a possible upside of 143.4% from the stock's current price.
View analysts' price targets for TFF Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are TFF Pharmaceuticals' key executives?

TFF Pharmaceuticals' management team includes the following people:
  • Mr. Glenn R. Mattes, Pres, CEO & Director (Age 66, Pay $516.67k)
  • Mr. Kirk Allen Coleman, CFO, Treasurer & Sec. (Age 49, Pay $281.91k)
  • Dr. James Brian Windsor, Chief Science Officer & Director (Age 55, Pay $150k)
  • Mr. Christopher Cano, COO & VP of Bus. Devel.

Who are some of TFF Pharmaceuticals' key competitors?

What other stocks do shareholders of TFF Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TFF Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), VBI Vaccines (VBIV), Akero Therapeutics (AKRO), VYNE Therapeutics (VYNE), Acer Therapeutics (ACER), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Chiasma (CHMA), Chimerix (CMRX) and DURECT (DRRX).

When did TFF Pharmaceuticals IPO?

(TFFP) raised $22 million in an initial public offering on Friday, October 25th 2019. The company issued 4,400,000 shares at $5.00 per share. National Securities served as the underwriter for the IPO.

What is TFF Pharmaceuticals' stock symbol?

TFF Pharmaceuticals trades on the NASDAQ under the ticker symbol "TFFP."

How do I buy shares of TFF Pharmaceuticals?

Shares of TFFP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TFF Pharmaceuticals' stock price today?

One share of TFFP stock can currently be purchased for approximately $12.12.

How much money does TFF Pharmaceuticals make?

TFF Pharmaceuticals has a market capitalization of $280.46 million. The company earns $-11,870,000.00 in net income (profit) each year or ($5.31) on an earnings per share basis.

How many employees does TFF Pharmaceuticals have?

TFF Pharmaceuticals employs 4 workers across the globe.

What is TFF Pharmaceuticals' official website?

The official website for TFF Pharmaceuticals is www.tffpharma.com.

Where are TFF Pharmaceuticals' headquarters?

TFF Pharmaceuticals is headquartered at 2600 Via Fortuna Suite 360, Austin TX, 78746.

How can I contact TFF Pharmaceuticals?

TFF Pharmaceuticals' mailing address is 2600 Via Fortuna Suite 360, Austin TX, 78746. The company can be reached via phone at 737-802-1973 or via email at [email protected]


This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.